First Human Study of CSPC's SYS6002 Presented at ASCO-GU

February 21, 2024

The 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was held in San Francisco. ASCO GU is an academic event in the field of male genitourinary tumors that will showcase the most innovative scientific advances in the field and explore the future treatment directions of male genitourinary tumors.

The phased results of the first human study of SYS6002, "Open, Single-arm and Multi-center Phase I Clinical Trial for Evaluating the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of SYS6002 in Patients with Advanced Solid Tumors", jointly conducted by CSPC and the teams of Professor Ye Dingwei and Professor Zhang Jian from Fudan University Shanghai Cancer Center, were presented in poster at the meeting (No. B622).

Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |